Thyroid,pork
Brand names: Adthyza, Armour Thyroid, Niva Thyroid, Np Thyroid, Thyroid
At a glance
- Medicare prescriptions, 2024
- 203,641
- Medicare drug cost
- $13.5M
- Average cost per prescription
- $66.20
- Clinicians who prescribed it
- 8,880
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Armour Thyroid (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer.
From the FDA-approved prescribing information (label dated January 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 32.8%
- Nurse Practitioners 17.4%
- Internal Medicine 16.9%
- Endocrinology & Diabetes 15.7%
- Physician Assistants 5.7%
- OB-GYN (Obstetrics & Gynecology) 2.7%
- Naturopaths 1.7%
- General Practice 1.4%
- Geriatric Medicine 0.8%
- Physical Medicine & Rehabilitation (PM&R) 0.4%
- Emergency Medicine 0.4%
- Allergy & Immunology 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 33% from 2019 to 2024.
Biggest change by state since 2019
- Texas +79%
- Illinois +67%
- Oregon +66%
- North Carolina +57%
- Arizona +56%
- Colorado (smallest change) −7%
- New Jersey (smallest change) +0%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 60 mg | brown round tablet, 7 mm | A TE |
Allergan, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 15 mg | brown round tablet, 5 mm | A TC |
| 30 mg | brown round tablet, 6 mm | A TD |
| 60 mg | brown round tablet, 7 mm | A TE |
| 90 mg | brown round tablet, 9 mm | A TJ |
| 120 mg | brown round tablet, 10 mm | A TF |
| 180 mg | brown round tablet, 10 mm | A TG |
| 240 mg | brown round tablet, 11 mm | A TH |
| 300 mg | brown round tablet, 13 mm | A TI |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $38,969 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- AbbVie Inc. $38,910
- Azurity Pharmaceuticals, Inc. $59
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Aug 2026 · Vitruvias Therapeutics Inc · Class I
Superpotent Drug
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Industry-funded trials
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.